Randomized, Double-Blind, Placebo-Controlled Study of Encenicline, an α7 Nicotinic Acetylcholine Receptor Agonist, as a Treatment for Cognitive Impairment in Schizophrenia

Encenicline is a novel, selective α7 nicotinic acetylcholine receptor agonist in development for treating cognitive impairment in schizophrenia and Alzheimer's disease. A phase 2, double-blind, randomized, placebo-controlled, parallel-design, multinational study was conducted. Patients with sch...

Descripción completa

Detalles Bibliográficos
Autores principales: Keefe, Richard SE, Meltzer, Herbert A, Dgetluck, Nancy, Gawryl, Maria, Koenig, Gerhard, Moebius, Hans J, Lombardo, Ilise, Hilt, Dana C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4864641/
https://www.ncbi.nlm.nih.gov/pubmed/26089183
http://dx.doi.org/10.1038/npp.2015.176

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4864641/
https://www.ncbi.nlm.nih.gov/pubmed/26089183
http://dx.doi.org/10.1038/npp.2015.176

Ejemplares similares